Trial Details

COMPLETED
Basic Information
Clinical ID c1751
Identifier NCT04557215
Trial Title Efficacy and Safety of Rifaximin With NAC in IBS-D
Trial URL Visit Original Page
Study Information
Study Results

YES

Conditions Irritable Bowel Syndrome With Diarrhea
Interventions DRUG: Rifaximin|DRUG: N-acetylcysteine|DRUG: Placebo
Participant Information
Sponsor Cedars-Sinai Medical Center
City Los Angeles
Country/Region United States
Enrollment Criteria
Sex Requirement ALL
Age Requirement ADULT, OLDER_ADULT
Study Design
Study Type INTERVENTIONAL
Phase PHASE1|PHASE2
Time Information
Start Date 2020-11-13
Primary Completion Date 2021-08-31
Completion Date 2022-10-30